Omega Healthcare Invts (NYSE:OHI) Stock, Quote.Headers.trade-ideas

Omega Healthcare Invts

Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

News

Dividends

Price Target

Markets

Analyst Ratings

Trading Ideas

Wall Street&#39;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Concept,Of,Business,Prosperity,And,Asset,Management,,Real,Estate,Investment

Pre-Market Outlook

Wall Street&#39;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

8 Best Dividend Challengers Stocks To Buy In September 2024

Wall Street&#39;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Investors Inc

OHIO ART CO by Ohio Art Company (The)

Ohio Valley Banc Corporation

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>)</h3>
<ul>
<li>Dividend Yield: 8.54%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and cut the price target from $6 to $4 on Dec. 19, 2024. This analyst has an accuracy rate of 69%.</li>
<li>RBC Capital analyst Michael Carroll downgraded the stock from Outperform to Sector Perform with a price target of $5 on May 14, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Nov.7, Medical Properties Trust reported worse-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest MPW news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8356f98b-748a-4a66-8e7b-6e4f0dc6db31" alt="" style="width:606px;height:auto" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.74%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Oct. 30, EPR Props posted better-than-expected quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest EPR new</a>s.</li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/25fde8ab-3a45-4b71-980a-0efe0c0d9950" alt="" style="width:631px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.39%</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Connor Siversky assumed an Overweight rating and increased the price target from $40 to $43 on Oct. 1, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Jan. 6, Omega Healthcare Investors named Matthew Gourmand as President.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">OHI news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png" alt="" class="wp-image-728777" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-768x711.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Wall Street's Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Management

Omega Healthcare Investors Appoints Matthew Gourmand As President; COO Dan Booth Resigns

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.08%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $33 to $39 on Sept. 4. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results and raised its FY24 adjusted FFO guidance.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png" alt="" class="wp-image-704244" style="width:688px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.60%</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and raised the price target from $17 to $18 on Dec. 18. This analyst has an accuracy rate of 76%.</li>
<li>Barrington Research analyst James Goss maintained an Outperform rating with a price target of $21 on Nov. 13. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 12, Outfront Media posted mixed quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png" alt="" class="wp-image-704245" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-768x717.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
<h3 class="wp-block-heading">LTC Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>)</h3>
<ul>
<li>Dividend Yield: 6.50%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Equal-Weight rating and raised the price target from $36 to $37 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Wedbush analyst Richard Anderson reiterated an Outperform rating and a price target of $40 on Sept. 20. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: LTC named Wendy Simpson Executive Chairman Of The Board, promoted Pam Kessler and Clint Malin to co-Chief Executive Officers, and Cece Chikhale Tto Chief Financial Officer, effective Dec. 31.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"> trend in LTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png" alt="" class="wp-image-704248" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-768x716.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

BMO Capital analyst Juan Sanabria upgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Market Perform to Outperform and maintains the price target from $45 to $45.

Upgrades

BMO Capital Upgrades Omega Healthcare Invts to Outperform, Maintains Price Target to $45

In the latest quarter, 5 analysts provided ratings for Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.6, a high estimate of $45.00, and a low estimate of $37.00. This current average has increased by 7.85% from the previous average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733410821_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Omega Healthcare Invts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Kai Klose</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Omega Healthcare Invts's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Get to Know Omega Healthcare Invts Better</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Financial Insights: Omega Healthcare Invts</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Omega Healthcare Invts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.05% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Omega Healthcare Invts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 40.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Omega Healthcare Invts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.82%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omega Healthcare Invts's ROA stands out, surpassing industry averages. With an impressive ROA of 1.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below the industry average at 1.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Omega Healthcare Invts: What You Need To Know

Mizuho analyst Haendel St. Juste maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Neutral and raises the price target from $35 to $37.

Mizuho Maintains Neutral on Omega Healthcare Invts, Raises Price Target to $37

In the current market session, Omega Healthcare Invts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) stock price is at $40.93, after a 1.10% drop. However, over the past month, the company's stock spiked by 1.67%, and in the past year, by 31.23%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1731431745_0.png" alt="Past Year Chart" />

<h3>A Look at Omega Healthcare Invts P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 45.15 in the Helath Care REITs industry, Omega Healthcare Invts Inc. has a lower P/E ratio of 30.43. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731431745_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Omega Healthcare Invts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.65%</li>
<li>Barrington Research analyst James Goss maintained an Outperform rating and raised the price target from $17 to $18 on Aug. 13. This analyst has an accuracy rate of 66%.</li>
<li>TD Cowen analyst Lance Vitanza initiated coverage on the stock with a Hold rating and a price target of $16 on July 16. This analyst has an accuracy rate of 80%.</li>
<li>Recent News: On Sept. 30, Scott Felenstein joined OUTFRONT Media as Senior Vice President of Brand Partnerships.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116.png" alt="" class="wp-image-642417" style="width:728px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12050955/image-116-768x692.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 6.47%</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Connor Siversky assumed coverage on the stock with an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117.png" alt="" class="wp-image-642420" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051035/image-117-768x696.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">RLJ Lodging Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>)</h3>
<ul>
<li>Dividend Yield: 6.12%</li>
<li>Truist Securities analyst Gregory Miller maintained a Buy rating and cut the price target from $14 to $11 on Oct. 28. This analyst has an accuracy rate of 68%.</li>
<li>Wolfe Research analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Nov. 6, RLJ Lodging posted better-than-expected quarterly sales.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">trend in RLJ stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118.png" alt="" class="wp-image-642422" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12051116/image-118-768x698.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

Across the recent three months, 6 analysts have shared their insights on Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.33, a high estimate of $45.00, and a low estimate of $39.00. Marking an increase of 11.98%, the current average surpasses the previous average price target of $37.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1731348010_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Omega Healthcare Invts among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Kai Klose</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Omega Healthcare Invts's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Discovering Omega Healthcare Invts: A Closer Look</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Understanding the Numbers: Omega Healthcare Invts's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Omega Healthcare Invts displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.05%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 40.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Omega Healthcare Invts's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Omega Healthcare Invts's ROA excels beyond industry benchmarks, reaching 1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Omega Healthcare Invts: 6 Analysts Share Their Views

RBC Capital analyst Michael Carroll maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Sector Perform and raises the price target from $39 to $43.

RBC Capital Maintains Sector Perform on Omega Healthcare Invts, Raises Price Target to $43

WIIM

Omega Healthcare Investors shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted FFO guidance.

Guidance

Omega Healthcare Investors Sees FY24 Adjusted FFO Per Diluted Share $2.84-$2.86 (Prior $2.78-$2.84)

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.72 by 2.78 percent. The company reported quarterly sales of $276.028 million which beat the analyst consensus estimate of $264.447 million by 4.38 percent. This is a 14.05 percent increase over sales of $242.032 million the same period last year.

Earnings

Earnings Beats

Omega Healthcare Invts Q3 2024 FFO $0.74 Beats $0.72 Estimate, Sales $276.028M Beat $264.447M Estimate

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $42.2, a high estimate of $45.00, and a low estimate of $39.00. This upward trend is apparent, with the current average reflecting a 12.53% increase from the previous average price target of $37.50.
<img src="https://www.benzinga.com/files/images/story/2024/1729263629_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Omega Healthcare Invts's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kai Klose</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Omega Healthcare Invts's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Get to Know Omega Healthcare Invts Better</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Omega Healthcare Invts's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Omega Healthcare Invts's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.02%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Omega Healthcare Invts's net margin excels beyond industry benchmarks, reaching 45.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Omega Healthcare Invts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omega Healthcare Invts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.27%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.26, Omega Healthcare Invts adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Omega Healthcare Invts

Berenberg analyst Kai Klose initiates coverage on Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Buy rating and announces Price Target of $45.

Initiation

Berenberg Initiates Coverage On Omega Healthcare Invts with Buy Rating, Announces Price Target of $45

BMO Capital analyst Juan Sanabria maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Market Perform and raises the price target from $44 to $45.

BMO Capital Maintains Market Perform on Omega Healthcare Invts, Raises Price Target to $45

A substantial insider sell was reported on October 2, by ROBERT STEPHENSON, Chief Financial Officer at Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), based on the recent SEC filing.
What Happened: STEPHENSON's decision to sell 22,542 shares of Omega Healthcare Invts was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000888491/000141588924024257//Archives/edgar/data/888491/000141588924024257/0001415889-24-024257-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $905,962.
In the Wednesday's morning session, Omega Healthcare Invts's shares are currently trading at $40.39, experiencing a down of 0.0%.
<h3>About Omega Healthcare Invts</h3>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Omega Healthcare Invts: Delving into Financials</h3>
Revenue Growth: Omega Healthcare Invts's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.02%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 98.52%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.46, Omega Healthcare Invts showcases strong earnings per share.
</li>
</ul>
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.26.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 30.6 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.65 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 17.0 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000888491">Check Out The Full List Of Omega Healthcare Invts's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Financial Officer Of Omega Healthcare Invts Makes $905K Sale

It was reported on October 2, that DANIEL BOOTH, Chief Operating Officer at Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) executed a significant insider sell, according to an SEC filing.
What Happened: After conducting a thorough analysis, BOOTH sold 56,725 shares of Omega Healthcare Invts. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000888491/000141588924024259//Archives/edgar/data/888491/000141588924024259/0001415889-24-024259-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $2,283,181.
In the Wednesday's morning session, Omega Healthcare Invts's shares are currently trading at $40.39, experiencing a down of 0.0%.
<h3>About Omega Healthcare Invts</h3>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Omega Healthcare Invts's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Omega Healthcare Invts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.02% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 98.52%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Omega Healthcare Invts's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.46.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.26.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 30.6 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.65 is above industry norms, reflecting an elevated valuation for Omega Healthcare Invts's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Omega Healthcare Invts's EV/EBITDA ratio at 17.0 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Exploring Key Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000888491">Check Out The Full List Of Omega Healthcare Invts's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Omega Healthcare Invts Insider Trades Send A Signal

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $38.5, a high estimate of $43.00, and a low estimate of $33.00. This current average reflects an increase of 11.59% from the previous average price target of $34.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727812873_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Omega Healthcare Invts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Omega Healthcare Invts's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Omega Healthcare Invts's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Delving into Omega Healthcare Invts's Background</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Omega Healthcare Invts's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Omega Healthcare Invts's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 1.02%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Omega Healthcare Invts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 45.05%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Omega Healthcare Invts's ROE excels beyond industry benchmarks, reaching 3.15%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Omega Healthcare Invts's ROA excels beyond industry benchmarks, reaching 1.27%. This signifies efficient management of assets and strong financial health.
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.26.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Omega Healthcare Invts Stock

Offerings

Omega Healthcare Investors Inc Files For Mixed Shelf; Size Not Disclosed

NAV Monitor: U.S. Equity REITs Close 2024 At 12.8% Median Discount

Omega Healthcare Investors: Covered Dividend And Transformation Make It A Buy

As the healthcare real estate market flourishes, fueled by demographic transformations and cutting-edge advancements in healthcare delivery, fundamentally robust stalwarts like Welltower (WELL), Ventas (VTR), and Omega Healthcare Investors (OHI) shine as premier investment opportunities. Dive deeper to discover how these REITs are shaping the future while delivering healthy returns... The healthcare real estate sector has emerged as a dynamic investment avenue, fueled by an aging population, rising demand for specialized medical facilities, and technological advancements. Healthcare REITs, which invest in properties like senior housing, medical offices, and outpatient centers, are benefiting from robust growth driven by demographic trends and the increasing prevalence of telemedicine.
So, it could be an ideal time to scoop up leading REIT stocks Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>), Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>), and Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>), which are capitalizing on new trends, providing robust dividend yields and attracting investor interest.
Additionally, the sector's resilience during the COVID-19 pandemic underscored the value of modern, adaptable facilities, further attracting institutional capital. Emerging markets, including Asia Pacific and Latin America, are also seeing growth due to rising incomes and government investments in healthcare.
The global healthcare real estate market is projected to grow at a <a href="https://www.grandviewresearch.com/industry-analysis/healthcare-real-estate-market-report">7.9% CAGR</a> through 2030.
Considering this upward trend, let's delve into the details of <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> stocks:
Stock #3: Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>) 
VTR is a leading REIT specializing in senior housing, medical buildings, and healthcare facilities across North America and the UK. Leveraging its operational expertise and Ventas OI platform, the company supports the aging population while driving growth and delivering strong financial performance.
On December 10, VTR announced a quarterly dividend of $0.45 per common share. The dividend will be paid in cash on January 16, to shareholders of record as of December 31, 2024. It pays an annual dividend of $1.80, which translates to a dividend yield of 3.16% at the prevailing price levels. Its four-year average dividend yield is 3.63%.
In the fiscal third quarter ended September 30, 2024, VTR's total revenues increased 7.5% year-over-year were $1.24 billion. In addition, the net income attributable to common stockholders came in at $19.24 million and $0.05 per share, compared to a loss of $71.12 million and $0.18 per share in the prior year quarter, respectively.
Street expects VTR's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the fiscal fourth quarter (ending December 31, 2024) to increase 7.7% year-over-year to $ 1.25 billion. Its FFO for the same quarter is expected to increase 5.7% year-over-year to $0.80. In addition, it surpassed the consensus revenue and FFO estimates in all of the trailing four quarters, which is promising.
Shares of VTR have gained 17.2% over the past year and 10% over the past six months to close the last trading session at $57.07.
VTR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
VTR has a B grade in Growth and Stability. It is ranked #9 out of 14 stocks in the <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a>.
Beyond what we have stated above, we also have given VTR grades for Value, Momentum, Sentiment, and Quality. Get all the VTR's ratings <a href="https://stocknews.com/stock/VTR/">here</a>.
Stock #2: Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>) 
WELL is a REIT that focuses on transforming healthcare infrastructure by investing in seniors housing, post-acute communities, and outpatient medical properties across high-growth markets in the U.S., Canada, and the UK.
It pays an annual dividend of $ 2.68, which translates to a dividend yield of 2.16% at the prevailing price levels. Its four-year average dividend yield is 2.94%. The company has grown its dividend payment at a CAGR of 1.6% over the past three years.
During the fiscal third quarter that ended September 30, 2024, WELL's total revenues increased 23.7% year-over-year to $2.06 billion. In addition, the company's net income attributable to common stockholders and net income attributable to common stockholders per share came in at $ 449.85 million and $0.73, up 252.9% and 204.2% over the prior-year quarter, respectively.
Analysts expect WELL's revenue and FFO for the fourth quarter ending December 31, 2024, to increase 25.1% and 16.7% year-over-year to $ 2.19 billion and $ 1.12, respectively. In addition, it surpassed the consensus revenue estimates in all of the trailing four quarters.
Shares of WELL have gained 38.3% over the past year and 19% over the past six months to close the last trading session at $124.24.
WELL's POWR Ratings reflect its robust outlook. It has an A grade for Sentiment and a B in Growth. It is ranked #8 in the same industry.
Click <a href="https://stocknews.com/stock/WELL/">here</a> to see WELL's ratings for Value, Momentum, Stability, and Quality.
Stock #1: Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>) 
OHI is a REIT specializing in financing and capital for the long-term healthcare sector, focusing on skilled nursing facilities across the U.S. and the UK. OHI partners with 81 operators to identify quality healthcare investments offering optimal risk/reward for investors.
It pays an annual dividend of $2.68, which translates to a dividend yield of 7.18% at the prevailing price levels. Its four-year average dividend yield is 8.40%.
OHI's total revenues increased 14% year-over-year to $276.03 million in the fiscal third quarter that ended on September 30, 2024. Its adjusted funds from operations came in at $ 203.07 million, up 11.5% year-over-year. Moreover, its net income available to common stockholders and earnings per common share available to common stockholders stood at $ 111.76 million and $0.42, up 22.3% and 13.5% over the prior-year quarter, respectively.
The market projects OHI's revenue for the fiscal fourth quarter (ending December 31, 2024) to increase 10.9% year-over-year to $226.28 million. Its FFO for the same quarter is likely to increase 6.4% year-over-year to $0.72. In addition, it surpassed the consensus FFO estimates in each of the trailing four quarters.
Shares of OHI have gained 20.1% over the past year and 9.2% over the past six months to close the last trading session at $36.89.
OHI's bright prospects are apparent in its POWR Ratings. It has a B for Quality. It is ranked #4 in the same industry.
Click <a href="https://stocknews.com/stock/OHI/">here</a> to see OHI's ratings for Growth, Momentum, Value, Stability, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
WELL shares fell $0.14 (-0.11%) in premarket trading Wednesday. Year-to-date, WELL has declined -1.42%, versus a 0.44% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/well-vtr-ohi-3-healthcare-reits-offering-healthy-dividend-yields/>3 Healthcare REITs Offering Healthy Dividend Yields</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare REITs Offering Healthy Dividend Yields

Recession Alert: What I Learned From The Global Financial Crisis

Omega Healthcare Investors: Improving Dividend Health

My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys

Truist lowered the firm's price target on Omega Healthcare (OHI) to $38 from $39 and keeps a Hold rating on the shares as part of a 2025 outlook fo...

Omega Healthcare price target lowered to $38 from $39 at Truist

AAPL

ABBV

AGNC

ALIZF

APLE

ARCC

AVGO

BABA

BASFY

BXSL

CBAUF

COLD

CSCO

CSWC

CTRE

EPRT

EQIX

FSNUF

GAIN

GILD

GLAD

GOOD

GSBD

HTGC

ILPT

INTC

JBGS

MAIN

MFIC

MSFT

NVDA

OBDC

PKST

REXR

RITM

SBAC

SBRA

SEMHF

SHEL

SITC

STAG

STWD

TRNO

VICI

WELL

Press Releases

Omega Reports First Quarter 2024 Results and Recent Developments

Omega Provides an Update on the LaVie Restructuring

Omega Announces Quarterly Dividend and Schedules Second Quarter Earnings Release Date and Conference Call

Omega Reports Second Quarter 2024 Results and Recent Developments

Omega Announces Third Quarter Earnings Release Date and Conference Call

Real Estate

Inspīr Carnegie Hill Wins 2024 Senior Living Development Award from The Americas Property Awards

Comments

Omega Healthcare Invts

Omega Healthcare Invts (OHI) Forecast

Omega Healthcare Invts (NYSE:OHI) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga